STOCK TITAN

Zynex Announces 1 Millionth Patient Milestone

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Zynex, Inc. (NASDAQ: ZYXI) has treated over 1 million patients through its pain management division, manufacturing and selling FDA-cleared non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The company also distributes and private labels high-quality devices and is bringing in-patient hospital monitoring devices through FDA clearance.
Positive
  • None.
Negative
  • None.

ENGLEWOOD, Colo., Aug. 10, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that, since its founding, the company has treated more than 1 million patients through its pain management division.

Zynex manufactures and sells the NexWave electrotherapy device, an FDA-cleared, prescription-strength, non-invasive, and non-opioid approach to managing acute and chronic pain. The company's pain management division also distributes and private labels several high-quality devices such as low-back support, cervical traction, bracing, and hot/cold therapy. Zynex is bringing a series of in-patient hospital monitoring devices through FDA clearance in addition to its pain management and therapeutic products.

Thomas Sandgaard, Founder and CEO, commented on the company's milestone, "I'm incredibly proud to have surpassed treating 1 million patients. Reaching such a tremendous landmark for the company is a testament to the tireless efforts and teamwork that each of our employees brings to this company.

"Our journey to this moment has been filled with challenges, growth, and triumphs, and it's awe-inspiring to think about the countless lives we've touched. Success is not measured merely in numbers, but also in the positive change we've effected through proven non-opioid pain relief."

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+949 694 9594

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-1-millionth-patient-milestone-301897681.html

SOURCE Zynex

Zynex, Inc. has treated over 1 million patients.

Zynex, Inc. manufactures and sells FDA-cleared non-invasive medical devices for pain management, rehabilitation, and patient monitoring.

Thomas Sandgaard commented on the company's milestone of treating over 1 million patients.

The ticker symbol for Zynex, Inc. is ZYXI.
ZYNEX INC

NASDAQ:ZYXI

ZYXI Rankings

ZYXI Latest News

ZYXI Stock Data

365.59M
15.72M
51.14%
31.25%
18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ENGLEWOOD

About ZYXI

zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.